Download Free Sample
Author
Muni Kumar Meravath is a seasoned Healthcare Market Research Analyst with over 6 years of experience in the healthc.....
JAK Inhibitors Market: Competitive Landscape, Pipeline, and Market Analysis 2024
JAK Inhibitors Market: Competitive Landscape, Pipeline, and Market Analysis 2024
Janus Kinase (JAK) is a family of intracellular, non-receptor tyrosine kinases that transduce cytokine-mediated signals via the JAK-STAT pathway. There are four JAK family members; JAK1, JAk2, JAk3, TYK2. The molecules that use the JAK/STAT signaling pathway are colony-stimulating factor, prolactin, growth hormone, and many cytokines. The mechanism of action (MOA) of the JAK inhibitors inhibitors involves the inhibition of one or more of the JAK enzymes, particularly JAK1, JAK2, JAK3, or TYK2. By blocking these enzymes, JAK inhibitors interfere with the signaling cascades triggered by cytokines, such as interleukins and interferons. When a cytokine binds to its respective receptor on the cell surface, it activates the associated JAK enzymes. The activated JAKs, in turn, phosphorylate (add a phosphate group to) specific signal transducer and activator of transcription (STAT) proteins. These phosphorylated STATs then dimerize, translocate to the nucleus, and regulate gene expression.
By inhibiting JAK enzymes, JAK inhibitors prevent the phosphorylation of STAT proteins and their subsequent nuclear translocation. This interruption of the JAK-STAT signaling pathway leads to the inhibition of the expression of pro-inflammatory genes and the modulation of immune responses. JAK inhibitors are used in the treatment of blood coagulation disorder, lymphoma, autoimmune disorder, rheumatoid arthritis, skin diseases, connective tissue diseases, neoplasms, etc. Increased prevalence of inflammatory conditions, such as rheumatoid arthritis, psoriasis, ankylosing spondylitis, and rising aging population, etc are the key drivers for the JAK inhibitor market. For instance, according to the Centers for Disease Control and Prevention, an estimated 1.3% of US adults (3 million) reported being diagnosed with IBD; either Crohn's disease or ulcerative colitis. The introduction of newer products by market players may look for opportunities that have a big impact on comprehensive research and development in JAK inhibitors. For instance, BMS launched the Sotyktu (Deucravacitinib) for the treatment of plaque psoriasis. Moreover, to address the difficulties in therapy, numerous market participants are developing innovative compounds. For instances, Incyte’s Itacitinib (INCB039110) for the indication of B cell lymphoma is under the various stages of clinical studies.
Key Market Developments:
Approved Drug Molecules and Brand Names for JAK Inhibitors Market:
Drugs under the Pipeline for JAK Inhibitors:
Clinical Activity and Developments of JAK Inhibitors:
Up until July 2023, there will be more than 50 companies with over 180 compounds that focus on various forms rheumatoid arthritis, and hematologic diseases. For these molecules, more than 1,500 of clinical trials are being conducted and majority are in phase-2, phase-3 clinical trials by the players across the globe. For instance,
|
Molecule Name |
Number of Studies |
|
Itacitinib (INCB039110) |
53 |
|
Ivarmacitinib (SHR0302) |
26 |
|
Deuruxolitinib (CTP-543) |
21 |
|
Brepocitinib (PF-06700841) |
20 |
|
Corectim (delgocitinib) |
19 |
The molecules such as Rinvoq (Upadacitinib) developed by AbbVie for the line of treatment for the treatment of rheumatoid arthritis, adults with active psoriatic arthritis, moderate to severe atopic dermatitis in adults and children 12 years of age and older whose disease did not respond to previous treatment, moderately to severely active ulcerative colitis, active ankylosing spondylitis, active non-radiographic axial spondyloarthritis, adults with moderately to severely active Crohn's disease. Moreover, Bristol Myers Squibb’s Sotyktu (Deucravacitinib) tablets for the treatment of moderate-to-severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy.
Total sale of AbbVie’s Rinvoq (Upadacitinib) for the fourth quarter ended were US$517 million in FY2021 in globally. Moreover, recently AbbVie submitted an application to the EMA seeking approval for Skyrizi (600 mg intravenous induction and 360 mg subcutaneous maintenance therapy) for the treatment of patients 16 years and older with moderate to severe Crohn's disease (CD). Increase incidence of autoimmune diseases, arthritis and ankylosing spondylitis seems to create lucrative opportunites for the JAK inhibitor market for the forecasted period. For Instance, according to the Centers for Disease Control and Prevention 2021, around there were 32.5 million adults affected with osteoarthritis in US and are the key drivers for JAK inhibitors market.
Latin America
Europe
Asia Pacific
Middle East
North America
Download Free Sample Report
Jakafi (Ruxolitinib), Olumiant (Baricitinib), Rinvoq (Upadacitinib), etc are the few FDA approved JAK Inhibitors.
Global sales of AbbVie’s Rinvoq (Upadacitinib) for the fourth quarter ended were US$517 million in FY2021.
Novartis, Eli Lilly, AbbVie, BMS, etc are few leading market players in JAK market.
Blood Coagulation Disorder, Lymphoma, Autoimmune Disorder, Rheumatoid Arthritis, Skin Diseases, Connective Tissue Diseases, Neoplasms, are the major indication of JAK Inhibitors.
There are more than 70 molecules that are in the Phase-1, Phase-2 and Phase-3 clinical development.
Key Market Players
Author
Muni Kumar Meravath is a seasoned Healthcare Market Research Analyst with over 6 years of experience in the healthcare domain, encompassing pharmaceuticals, medical devices, and diagnostics. A graduate in Pharmacy, he possesses a strong foundation in the intricacies of the healthcare sector. He further enhanced his expertise by pursuing an MBA in Pharmaceuticals, equipping him with valuable business acumen. His analytical skills and market insights have contributed to strategic decision-making and enhanced market positioning for various healthcare organizations. Committed to driving innovation and excellence, Muni continues to seek opportunities to improve healthcare delivery through data-driven insights.